For the quarter ending 2025-09-30.
| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 |
|---|---|---|---|---|
| Revenues | - | - | 143,000 | 115,500 |
| Revenues-Product | 226,000 | 212,000 | - | - |
| Cost of revenues | 18,000 | 14,000 | 11,000 | 10,500 |
| Gross profit | 208,000 | 198,000 | 132,000 | 107,500 |
| Selling, general and administrative | 2,953,000 | 2,881,000 | 3,485,000 | 2,877,000 |
| Research and development | 276,000 | 155,000 | 103,000 | 64,000 |
| Acquired in-process research and development | 0 | 1,848,000 | 119,000 | - |
| Total operating expenses | 3,229,000 | 4,884,000 | 3,707,000 | 2,941,000 |
| Operating loss | -3,021,000 | -4,686,000 | -3,575,000 | -2,833,500 |
| Interest income | 10,000 | 3,000 | 18,000 | 20,250 |
| Interest expense-Nonrelated Party | 35,000 | - | - | - |
| Interest expense | - | - | 49,000 | 22,750 |
| Interest expense-Service | - | 67,000 | - | - |
| Interest expense-Related Party | 48,000 | - | - | - |
| Change in fair value of royalties payable due to related parties | 726,000 | -1,667,000 | -1,163,000 | -559,750 |
| Change in fair value of trading debt securities | 107,000 | 10,000 | - | - |
| Other expenses, net | -5,000 | -1,000 | - | -3,000 |
| Total other income (expenses), net | 755,000 | -1,722,000 | -1,194,000 | -564,750 |
| Loss from operations before income tax benefit (provision) | -2,266,000 | -6,408,000 | -4,769,000 | -3,375,500 |
| Income tax benefit (provision) | 78,000 | -950,000 | -724,000 | 785,250 |
| Net loss | -2,344,000 | -5,458,000 | - | - |
| Less net loss attributable to non-controlling interest | -93,000 | -349,000 | - | - |
| Net loss attributable to catheter precision, inc | -2,251,000 | -5,109,000 | -4,045,000 | -4,151,500 |
| Deemed dividend on warrant inducement offer | - | - | - | 1,289,500 |
| Net loss attributable to common stockholders | - | - | - | -5,450,250 |
| Net loss per share attributable to catheter precision, inc., basic and diluted (in dollars per share) | -1.7 | -0.38 | -0.36 | -1.67 |
| Weighted-average common shares used in computing net loss per share, basic and diluted (in shares) | 1,320,554 | 13,336,088 | 11,283,929 | 815,896.5 |
Catheter Precision, Inc. (VTAK)
Catheter Precision, Inc. (VTAK)